Lemme Reset vs Arrae MB-1: An Honest Head-to-Head

Two capsules keep getting put side by side in the "natural GLP-1" aisle: Lemme Reset — sold until 2026 as Lemme GLP-1 Daily, from the supplement brand co-founded by Kourtney Kardashian Barker — and Arrae MB-1, marketed to women as a "natural Faux-Zempic." Both are premium botanical capsules. Both borrow the vocabulary of a drug class. Neither one is a drug. This page sets them against each other on the only three questions that decide a purchase: what is actually in the bottle, what those ingredients have actually been tested for, and what each one costs.

Here is the short version, stated plainly so no one can miss it: neither product contains a GLP-1 drug, semaglutide, tirzepatide, or any prescription medicine of any kind. Both are built from botanical extracts whose human evidence is ingredient-level, modest, and measured mostly on surrogate endpoints — blood-sugar markers, snacking, energy expenditure, fat mass — rather than on measured weight loss. And neither finished product has a published weight-loss trial. Choosing between them is choosing between two mild, ingredient-level supports, not between two versions of Ozempic.

What's actually in each bottle

These are not two variations on one theme. Lemme Reset is narrow — three branded, standardized extracts. Arrae MB-1 is broad — seven inputs, several of them familiar weight-management shelf ingredients that have been sold on their own for years. The difference in shape matters, because a narrow formula has more room to deliver each active at the dose that was studied, and a seven-input capsule has less.

Lemme Reset: three actives. Eriomin lemon-fruit flavonoids at 200 mg, Supresa saffron at 176.5 mg, and Morosil red-orange extract at 400 mg per two-capsule serving — the doses we verified on Lemme's own product page on August 30, 2026, the same day we confirmed the rename from GLP-1 Daily. Eriomin is the ingredient that earns the "GLP-1" in the name: in a crossover randomized clinical trial in people with prediabetes it reduced blood glucose and was reported to increase glucagon-like peptide-1 by roughly 17%, alongside lower inflammation¹. An earlier double-blind randomized controlled trial in prediabetic adults found it lowered fasting glucose and helped reverse the prediabetes state in a meaningful share of participants over 12 weeks², and a later trial showed it shifted the gut microbiome in prediabetes³. Saffron's support is a single eight-week randomized placebo-controlled study in mildly overweight women, which found reduced between-meal snacking and increased self-reported satiety versus placebo⁴. Morosil's is a randomized, double-blind, placebo-controlled study in overweight-but-healthy adults that reported reductions in body weight and waist and hip circumference⁵, with an earlier Moro orange-juice study reporting modest weight-management signals⁶. The full breakdown is in our Lemme Reset review.

Arrae MB-1: seven inputs. African mango (Irvingia gabonensis) seed extract, Cissus quadrangularis extract, grains of paradise (Aframomum melegueta), the probiotic Bifidobacterium animalis subsp. lactis 420 (B420), green tea extract, vitamin B6, and chromium picolinate. African mango anchors the dramatic numbers: a frequently-cited randomized, double-blind, placebo-controlled trial of a standardized seed extract (IGOB131) reported a large body-weight reduction versus placebo over ten weeks⁷ — but an independent systematic review of the Irvingia gabonensis randomized trials concluded the studies were of poor methodological quality and the evidence too weak to support a firm weight-loss claim⁸. Green tea catechins plus caffeine have a real but small thermogenic effect: a meta-analysis found a statistically significant but modest effect on body weight and weight maintenance⁹, on the order of a kilogram and dependent on hitting a meaningful catechin dose. Chromium is settled and unimpressive — a Cochrane review found only a very small effect on body weight, of uncertain clinical relevance¹⁰. Grains of paradise has a genuinely interesting mechanism study: a small trial in men found the extract activated brown adipose tissue and increased whole-body energy expenditure¹¹, which here means roughly a few dozen extra calories burned. B420 controlled body-fat mass versus control in a randomized trial¹², and a later randomized trial of a B420-containing synbiotic reported shifts in the gut microbiome and metabolism during weight management¹³. Cissus has only mixed, inconsistent trial evidence, and B6 is a routine vitamin with no weight-loss effect on its own. The long version is in our Arrae MB-1 review.

What each has actually been tested for

This is where the head-to-head gets interesting, because the two formulas fail the same test in different ways. Read each ingredient's trial for the outcome it measured, not the outcome the product name implies.

On the Lemme side, the strongest single piece of evidence across either bottle is Eriomin — and what it demonstrated is a glucose and GLP-1 marker effect in prediabetics over about 12 weeks¹², not weight loss in healthy shoppers. Saffron's finding is a snacking and satiety effect, not measured weight⁴. Morosil is the only Lemme ingredient whose trial directly measured body weight and waist, and that effect is modest and rests largely on one study⁵. So the formula is one glucose-marker ingredient, one appetite-behavior ingredient, and one modest waistline ingredient.

On the Arrae side the pattern is different: more ingredients, none stronger. The biggest number in the marketing comes from the one trial an independent systematic review flagged as poor quality⁷⁸. Green tea's effect is about a kilogram and dose-dependent⁹; chromium's is very small and of uncertain relevance¹⁰; grains of paradise measured energy expenditure, a mechanism signal rather than a weight outcome¹¹; B420's results are fat-mass and microbiome effects from probiotic trials¹²¹³. Arrae advertises this as being "backed by 15 clinical trials" — which means the seven ingredients have roughly fifteen studies between them, run at different doses in different populations, not that MB-1 was tested fifteen times. The companion figure, "over 357,000 women," is a customer count, not a research result; it has no placebo control and is not a clinical endpoint.

The thing both products share is the gap that matters most. Each ingredient trial tested a specific dose of a single extract, often in a specific population — prediabetics, overweight women, men in a thermogenesis study. Neither finished capsule has been run through its own published randomized weight-loss trial. "Each ingredient has a study" is not the same claim as "this product has a study," and on that point Lemme Reset and Arrae MB-1 are tied at zero.

What each one costs

As of August 30, 2026, Lemme Reset sells on Lemme's site for $80 as a one-time purchase or $64 a month on subscription — 60 capsules, a 30-day supply. Arrae MB-1 sells in the premium range typical of the category, roughly $50 to $70 for a one-month supply, less on subscription; that is a category-range figure rather than a single price we re-verified on the day, so treat it as approximate in a way the Lemme number is not.

Read together, Arrae's range sits below Lemme's, though the two overlap: the top of MB-1's range is above Lemme's subscription price. Neither is cheap, and that is the point of asking the evidence question before the checkout question. At $50 to $80 a month, either product is a real line item for a mild, ingredient-level effect that no finished-product trial has measured.

The marketing, and what a regulator and a court docket have done with it

Both products are sold on language borrowed from medicine, and in both cases that language has drawn outside attention — but of very different kinds, and the distinction is worth being precise about.

Arrae's case is a completed regulatory finding. In 2025 the UK's Advertising Standards Authority upheld a ruling against MB-1's advertising, finding that consumers were likely to understand the "Faux-Zempic" framing to mean the product had effects equivalent to Ozempic, that the ads made unauthorized medicinal and health claims, and that referencing a specific rate of weight loss breached the rules for food supplements. A regulator looked at the marketing and ruled on it.

Lemme's case is open litigation, which is a different thing entirely. Proposed class actions have been filed over the product's "natural GLP-1" marketing — most recently Tiberia v. Lemme Inc. (No. 2:26-cv-07581, U.S. District Court for the Central District of California), filed on July 13, 2026, with earlier proposed class actions filed in 2025. No court has ruled on any of them, and nothing in this comparison is graded up or down because they exist. A lawsuit discloses; it does not re-grade evidence. What we will note on the record is that Lemme's own product page now states the product "does not contain GLP-1 or synthetic GLP-1 and is not a GLP-1 agonist drug" — a distinction the brand now makes in its own words, and one that MB-1's "Faux-Zempic" framing still blurs.

Who should pick which

Pick Lemme Reset if your concern is blood sugar rather than the scale. It is the only bottle here carrying an ingredient with more than weak human evidence: Eriomin, a reasonably well-studied lemon flavonoid with randomized glucose and GLP-1 marker data in prediabetics, with a saffron snacking nudge attached. If you have prediabetes or mild blood-sugar concerns and you can absorb $80 one-time or $64 a month, that is a defensible purchase — provided you treat any scale movement as a pleasant surprise layered on top of diet, protein, fiber and sleep.

Pick Arrae MB-1 if you want the broader, generally cheaper monthly capsule and you are explicitly buying mild metabolism support rather than a weight-loss result. Green tea and B420 are reasonable supplement choices on their own merits. Go in knowing that its most dramatic advertised number rests on the single trial a systematic review rated poor quality⁷⁸, that "15 trials" and "357,000 women" are not proof of the finished product, and that a regulator has already ruled its central comparison misleading.

Pick neither if what you actually want is drug-like weight loss. This is the honest case, and it applies to both. The pivotal STEP 1 trial of semaglutide produced about 15% mean body-weight loss over 68 weeks by saturating the GLP-1 receptor at supraphysiologic levels¹⁴. Against that, Lemme's best signal is a roughly 17% rise in your own GLP-1 marker in prediabetics¹ and Arrae's is a kilogram-scale ingredient effect⁹ — an order of magnitude apart, and a different category of intervention rather than a smaller version of the same one. We lay that magnitude gap out in full in supplements vs GLP-1 drugs.

The bottom line

Lemme Reset and Arrae MB-1 are two premium botanical capsules sold on adjacent promises, and the honest head-to-head is closer than either brand's marketing would suggest — because both sit low. Lemme wins on evidence quality by a narrow margin: three ingredients instead of seven, dosed transparently, with one active (Eriomin) whose randomized glucose and GLP-1 marker data is the only finding on either label we grade above weak. Arrae wins on breadth and usually on price, but its headline evidence is its weakest link, and its central comparison to Ozempic has already been ruled misleading by an advertising regulator. Neither contains a drug, neither has a finished-product weight-loss trial, and neither should be bought as a substitute for one. For where both land against everything else we have vetted, see our best natural GLP-1 supplements guide, and for the framework behind these grades, start with our pillar, 'natural GLP-1' supplements: what the evidence shows.